Regeneron wants expanded authorization for COVID treatment
New research shows that these treatments can significantly reduce the risk of infection, hospitalization, and death in high risk cases.
•
Jan 27, 2021, 12:24 PM
•
Updated 1,276 days ago
Share:
More Stories
Hometown Heroes in the Hudson Valley
2ds ago1:28
Medical experts recommend to still take precautions following CDC's revised COVID isolation guidelines
146ds ago1:52
Judge: 3 men convicted in COVID-19 relief aid fraud
167ds ago1:47
Wondrous Things store in Briarcliff Manor to close after 34 years; everything 25% off
294ds ago0:28
Rockland small businesses get COVID-19 reimbursement grant
295ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds agoHometown Heroes in the Hudson Valley
2ds ago1:28
Medical experts recommend to still take precautions following CDC's revised COVID isolation guidelines
146ds ago1:52
Judge: 3 men convicted in COVID-19 relief aid fraud
167ds ago1:47
Wondrous Things store in Briarcliff Manor to close after 34 years; everything 25% off
294ds ago0:28
Rockland small businesses get COVID-19 reimbursement grant
295ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds agoRegeneron and Eli Lilly are
now asking regulators to expand authorization on their antibody treatments just
one day after promising new research was released.
Right now both companies
produce treatments that have been approved for emergency use in mild or
moderate COVID-19 cases.
But as News 12 has reported,
this new research shows that these treatments can significantly reduce the risk
of infection, hospitalization, and death in high risk cases.
Regulators say they are
holding off on a decision until more research is done.